Pfizer taps HIV, hep C antiviral research for COVID-19 pill trial Biogen holds firm on denying compassionate use for experimental ALS drug BrainStorm climbs on stem cell data from small multiple sclerosis trial Sponsored: NK Cells are Now Better Serial Killers Zimmermann replaces ex-Roche pRED chief as Inotrem CEO 3B Future Health launches 2nd fund for U.S., European early-stage biotechs CureVac's COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant Evidation Health scores $153M to further transform its virtual research programs into digital interventions GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D site Featured Story | By Ben Adams Pfizer has already seen major success with its BioNTech-partnered COVID-19 vaccine, but, now, the Big Pharma is hoping to add to the arsenal with a pandemic pill using old antiviral technology. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Nearly 70,000 people have signed an online petition asking Biogen to provide an experimental ALS drug to a patient requesting it under compassionate use, but the pharma is sticking to its decision not to offer the treatment. read more By Nick Paul Taylor BrainStorm Cell Therapeutics has presented phase 2 data on its stem cell therapy in patients with multiple sclerosis. The small, open-label clinical trial linked autologous therapy NurOwn to a 25% improvement in measures of mobility and dexterity in around 14% of patients. read more Sponsored By: GT Biopharma, Inc. Could native, non-functioning NK cells in cancer patients be rescued and revived by a novel, off-the-shelf immuno-oncology therapeutic that is also a pervasive serial cancer killer? The Data Says Yes. read more By Nick Paul Taylor Inotrem has named Sven Zimmermann as CEO. Zimmermann joins the inflammatory disease biotech after overseeing a series of deals at former employers including Novimmune’s asset sale to Sobi and Auris Medical’s IPO. read more By Ben Adams European life sciences VC 3B Future Health Ventures is targeting €100 million and partnering with “experienced private and institutional investors” with its second fund. read more By Angus Liu Emerging coronavirus variants threaten the potency of existing COVID-19 vaccines, sending their manufacturers on a quest to develop booster shots. CureVac, which is in late-stage testing of its mRNA shot, now has mouse data showing its product could stave off one aggressive COVID-19 variant first identified in South Africa. read more By Conor Hale Evidation plans to build out its digital Achievement program, which signs up participants for research studies from a pool of over 4 million users. read more By Arlene Weintraub GlaxoSmithKline has fired company veteran Moncef Slaoui from the board of its majority owned Galvani Bioelectronics, following allegations from a GSK employee of sexual harassment. GSK CEO Emma Walmsley told employees she is "shocked and angry" and that the company will rename its Slaoui Center for Vaccines Research. read more Resources Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: OCT Clinical Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical. Sponsored By: Almac Clinical Technologies This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: AmerisourceBergen Corporation Unlock product potential by making the most of your commercialization investments. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: Acorn AI Unlock competitive advantage with AI and advanced analytics. Sponsored By: EVERSANA Mature brands lost billions in revenue and value during COVID, but with the right strategy, pharma can rebound and reignite revenue. Learn How. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Thermo Fisher Scientific Involved in vaccine development? Check out this timely infographic detailing the history of vaccines, key development milestones, and what challenges remain. Sponsored By: Blue Matter, strategic consultants in the life sciences A look ahead at how cell-based therapies in oncology will advance during 2021-22: research, regulatory, and commercial milestones. Sponsored by: Baxter BioPharma Solutions While service directories are filled with CMOs claiming vaccine fill-finish experience, the logistical challenges resulting from seasonal product are unique and it is important that outsourcing partners can ensure quality and on-time delivery. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Global Clinical Quality April 7-8, 2021 | Virtual Event Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Pharma PR & Communications Virtual Summit April 20–22, 2021 | Virtual Event Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST | 